Denali Therapeutics (DNLI) Announces Earnings Results

Denali Therapeutics (NASDAQ:DNLI) issued its earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.13), Fidelity Earnings reports. The business had revenue of $1.20 million for the quarter, compared to analysts’ expectations of $3.00 million.

NASDAQ DNLI traded down $0.67 during trading hours on Friday, reaching $16.68. The company’s stock had a trading volume of 207,840 shares, compared to its average volume of 368,850. Denali Therapeutics has a 52 week low of $12.32 and a 52 week high of $25.79. The stock has a market capitalization of $1.65 billion and a P/E ratio of -2.83.

In other news, insider Ryan J. Watts sold 18,334 shares of Denali Therapeutics stock in a transaction that occurred on Wednesday, August 29th. The stock was sold at an average price of $18.05, for a total transaction of $330,928.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Carole Ho sold 17,500 shares of Denali Therapeutics stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $21.72, for a total value of $380,100.00. The disclosure for this sale can be found here. Insiders sold 54,167 shares of company stock worth $1,060,456 in the last three months. 21.30% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Denali Therapeutics stock. Bank of New York Mellon Corp raised its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 17.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 61,196 shares of the company’s stock after acquiring an additional 8,882 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.06% of Denali Therapeutics worth $933,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 65.06% of the company’s stock.

Separately, Zacks Investment Research cut shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $23.25.

TRADEMARK VIOLATION NOTICE: This story was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

See Also: Diversification in Investing

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply